31181-64-3

Basic information

• Product Name: 5-BROMO-2-METHYLPYRIDINE N-OXIDE
• Synonyms: SPECS AC-907/25004519;5-BROMO-2-METHYLPYRIDINE N-OXIDE;2-METHYL-5-BROMOPYRIDINE-N-OXIDE;5-BROMO-2-METHYLPYRIDINE 1-OXIDE;5-BROMO-2-METHYLPYRIDINE-N-OXIDE,SPECIFICATION: =98.5%(HPLC UV);5-Methyl-5-bromopyridine-N-oxide;5-broMo-2-Methyl-1$l^{5}-pyridin-1-one;5-bromo-2-methyl-1-oxidopyridin-1-ium
• CAS NO: 31181-64-3
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02
• Product Categories: alkyl bromide
• Mol File: 31181-64-3.mol
• Article Data: 24

Chemical Properties

• Melting Point: 119.5-120.1 °C
• Boiling Point: 345.7 °C at 760 mmHg
• Flash Point: 162.9 °C
• Appearance: /
• Density: 1.56 g/cm³
• Vapor Pressure: 0.00012mmHg at 25°C
• Refractive Index: 1.577
• PKA: 0.40±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2-METHYLPYRIDINE N-OXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-METHYLPYRIDINE N-OXIDE(31181-64-3)
• EPA Substance Registry System: 5-BROMO-2-METHYLPYRIDINE N-OXIDE(31181-64-3)

Safety Data

• Hazardous Substances Data: 31181-64-3(Hazardous Substances Data)

Usage

Chemical Properties

Type of white crystal

InChI:InChI=1/C6H6BrNO/c1-5-2-3-6(7)4-8(5)9/h2-4H,1H3

Upstream product

• 109-06-8 α-picoline 
• 3430-13-5 5-bromo-2-methylpyridine 

Downstream Products

• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 192642-82-3 6-bromo-[1,2,3]triazolo[1,5-a]pyridine 
• 192642-97-0 (E,Z)-N’-((5-bromopyridin-2-yl)methylene)-4-methylbenzene-sulfonohydrazide 
• 1070972-66-5 4-chloro-5-(4-chloro-6-methyl-pyridin-3-yl)-2-fluoro-N-(2-methoxy-phenyl)-N-methyl-benzenesulfonamide 
• 1003711-85-0 5-bromo-4-chloro-2-methylpyridine 
• 779344-30-8 3-bromo-6-methyl-2-pyridinecarboxylic acid 
• 1060810-14-1 3-bromo-6-methyl-2-pyridinecarboxaldehyde 
• 1335050-19-5 5-bromo-2-(2,2,2-trifluoroethyl)pyridine 
• 1260162-97-7 N-[5-(3-chlorophenyl)-2-methylpyridin-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1060802-25-6 5-bromo-4-chloropicolinic acid 
• 168823-76-5 5-bromo-2-(chloromethyl)pyridine 
• 380893-73-2 [(5-bromo-2-pyridinyl)methyl]-phosphonic acid diethyl ester 
• 1260162-47-7 N-(5-(2,5-dichlorophenyl)-2-methylpyridin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 717843-48-6 3-bromo-6-methylpyridine-2-carbonitrile 

Relevant articles and documents

IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF

The present disclosure provides compounds represented by Formula (I) wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula (I) are FED inhibitors. FED inhibitors are useful for the treatment of cancer and other diseases.

Full synthesis of natural-product (+/-)-cananga odorata alkali and separation method of enantiomers

The invention discloses full synthesis of natural-product (+/-)-cananga odorata alkali and a chiral separation method of enantiomers thereof and belongs to the technical field of organic synthesis. The chiral separation method comprises the following steps of: adopting natural-product (+/-)-anthorine G as a substrate, carrying out tetrahydrofuran/methyl lithium reaction to obtain the natural-product (+/-)-cananga odorata alkali and the enantiomers thereof; then using a chiral semi-preparative type high-performance liquid chromatograph to carry out separation on the enantiomers, and obtaining the cananga odorata alkali and the enantiomers with the total yield being 17.9%. The full synthesis and the chiral separation method disclosed by the invention have the beneficial effects that the synthesis method is simplified, the total yield of full synthesis is increased, the structure identification is carried out, and not only is the divergence on the specific rotation of the cananga odorataalkali solved, but also basis and powerful guarantee are provided for further study on the compounds.

INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF

The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as i